Showing results (241-250 of 651) with videos related to

Sort By:
Pageof 66
Frontiers in Pharmacology|May 16, 2022
Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator ReceptorViktor Rotbain Curovic, Morten B Houlind, Tine W Hansen, et al.
Journal of Translational Medicine|July 6, 2016
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitusMichelle J Pena, Andreas Heinzel, Peter Rossing, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 17, 2026
Workforce Detachment in Persons with Chronic Kidney DiseaseRasmus Rørth, Milos M Koch, Thomas A Gerds, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 6, 2023
Urinary peptide analysis to predict the response to blood pressure medicationMayra Alejandra Jaimes Campos, Emmanouil Mavrogeorgis, Agnieszka Latosinska, et al.
European Heart Journal. Cardiovascular Imaging|July 23, 2019
Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetesMats Christian Højbjerg Lassen, Magnus T Jensen, Tor Biering-Sørensen, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|October 31, 2012
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney diseaseStine E Nielsen, Katrine J Schjoedt, Kasper Rossing, et al.
Diabetes Care|June 9, 2009
Tubular and glomerular injury in diabetes and the impact of ACE inhibitionStine E Nielsen, Takeshi Sugaya, Lise Tarnow, et al.
Cardiovascular Diabetology|August 5, 2011
NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosisHenrik Reinhard, Niels Wiinberg, Peter R Hansen, et al.
Diabetes Research and Clinical Practice|March 10, 2012
Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patientsStine E Nielsen, Henrik Reinhard, Dietmar Zdunek, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2020
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trialsJohannes F E Mann, Thomas Hansen, Thomas Idorn, et al.
Pageof 66